GE HealthCare (GEHC) announced that it has received FDA premarket authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Strategic Acquisition of Intelerad Boosts GE Healthcare’s SaaS Offerings and Revenue Potential
- GE Healthcare’s Strategic Acquisition of Intelerad: Balancing Long-Term Gains with Short-Term Challenges
- Hold Rating on GE Healthcare Technologies Inc: Strategic Acquisition of Intelerad Brings Long-Term Growth Potential Amid Initial EPS Dilution Concerns
- GE Healthcare’s Intelerad Acquisition: Balancing Long-term Growth with Short-term EPS Dilution
- GE HealthCare to acquire Intelerad for $2.3B in cash